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Abstract
Background: Thyroid hormones are known to have direct and indirect effects on metabolism. Individuals with
metabolic syndrome, a disease that is growing in incidence at a rapid rate, are at higher risk for cardiovascular
disease, diabetes, and cancer. The aim of this study was to identify whether significant correlations exist between
thyroid hormone levels and components of the metabolic syndrome in the general population of Korea.
Methods: The data were collected from the sixth Korea National Health and Nutrition Examination Surveys from
2013 to 2015. A total of 1423 participants were tested for thyroid function. The analysis of variance and multiple
linear regression were performed to analyze the relationship between thyroid hormone level and components of
the metabolic syndrome.
Results: A positive association between free thyroxine and fasting glucose level was observed in patients with high
free thyroxine levels (≥1.70 ng/dL, β = 15.992, p = < 0.0001), when compared with patients with normal-middle free
thyroxine levels. Moreover, a negative association was observed between free thyroxine and triglyceride levels in
patients with normal-high free thyroxine levels (β = − 21.145, p = 0.0054) and those with high free thyroxine levels
(β = − 49.713, p = 0.0404).
Conclusion: Free thyroxine shows a partially positive association with fasting glucose and a partially negative
association with triglycerides in the Korean population. In patients with abnormal thyroid function, follow up tests
for glucose levels and lipid profiling during treatment for thyroid dysfunction would be beneficial in terms of
overlooking metabolic syndrome and to prevent related diseases.
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Background
Metabolic syndrome, a well-known cluster of cardiovas-
cular risk factors, is a major public health concern
worldwide [1, 2]. Metabolic syndrome increases the risk
for cardiovascular disease, diabetes, and even certain
types of cancer [3]. According to the National Choles-
terol Education Program’s Adult Treatment Panel III
definition, metabolic syndrome is the presence of abnor-
mal values for at least three of the following criteria:
waist circumference, serum triglycerides, high-density
lipoprotein (HDL) cholesterol, blood pressure, and fast-
ing glucose [3]. The prevalence of metabolic syndrome
is increasing rapidly [4]. According to data from the Na-
tional Health and Nutrition Examination Survey
(NHANES) 2011–2012, about 34.7% of US adults were
estimated to have metabolic syndrome [4]. Similar in-
creasing trends have been observed in Europe and other
countries [2, 5]. According to the National Cholesterol
Education Program’s Adult Treatment Panel III criteria,
and per the World Health Organization Asia-Pacific
guidelines, the prevalence of metabolic syndrome was
approximately 28.2% in the general population of Korea
in 2012 [6]. The mortality rate due to cardiovascular dis-
ease has increased from 35.6 to 52.4 out of 100,000 per-
sons over 2003–2014. Thus, more focus and effort is
needed to reduce the prevalence of metabolic syndrome,
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while considering the rapidly increasing frequency of
mortality due to related diseases [7].
Thyroid hormones have an important role in metabol-
ism [8]. Abnormal levels of thyroid hormones alter me-
tabolism, and some of these changes share common
pathophysiologic processes with metabolic syndrome.
Therefore, thyroid dysfunction can affect metabolic syn-
drome. Lambadiari et al. reported that thyroid hormones
are significant determinants of glucose homeostasis [9],
and affect fasting glucose levels by antagonizing insulin
action [9]. For instance, hyperthyroidism leads to im-
paired insulin secretion, which suppresses hepatic glu-
cose production and promotes glucose uptake in the
muscle [9]. Similarly, Dimitriadis et al. showed that the
increased glucose levels in hyperthyroidism could be ex-
plained by an increase in endogenous glucose produc-
tion via of gluconeogenesis [10]. Studies have also
demonstrated an association between thyroid hormones
and glucose levels. Klein et al. reviewed several studies
regarding the mechanism of action of thyroid hormones
on the cardiovascular system [11]. They concluded that
thyroid hormones have direct and indirect impacts on
the cardiovascular system. Patients with thyroid disease,
especially hyperthyroidism, often demonstrated signs
and symptoms of cardiovascular changes [11]. Several
other studies have shown that overt hypothyroidism in-
duces an increase in blood pressure and plasma choles-
terol levels [12]. However, most of the studies that
assessed the relationships between abnormal thyroid
hormone levels and metabolic syndrome have been con-
ducted in Caucasian populations [2, 13]. Therefore, the
aim of this study was to assess the relationships between
thyroid hormone levels and metabolic syndrome compo-
nents in a nationally representative sample of South Ko-
rean adults.
Methods
Study population
This study was conducted using data from the sixth
Korea National Health and Nutrition Examination
Surveys (KNHANES VI, 2013–2015), a nationwide
cross-sectional survey conducted by the Korean Cen-
ters for Disease Control and Prevention (Seoul,
Korea) to assess the health and nutritional status of
the South Korean population. The institutional review
board of the Korea Centers for Disease Control and
Prevention (KCDC) approved the study (IRB:
2013-07CON-03-4C, 2013-12EXP-03-5C, 2015–
01-02-6C). A nationally representative sample was ob-
tained using a stratified multistage cluster sampling
design. The survey consists of a health interview, nu-
trition survey, and health examination. Tests for thy-
roid disease and metabolic syndrome components
(waist circumference, triglycerides, HDL cholesterol,
blood pressure, and fasting glucose) were part of the
health examination. The initial sample included
22,948 participants. The thyroid functions tests were
carried out by subsampling 2400 subjects aged
≥10 years with respect to thyroid-stimulating hor-
mone (TSH), free thyroxine (FT4), thyroid peroxidase
antibody (TPOab), and urinary iodine in the sixth
Korea National Health and Nutrition Examination
Surveys (KNHANES VI, 2013–2015). Participants with
missing thyroid function data were excluded (n =
20,591). Patients who received treatment that could
interfere with the test results for thyroid hormone
levels and various components of metabolic syn-
drome, such as radioactive iodine treatment, antithy-
roid drugs, thyroid hormones, other medication for
thyroid disease, dyslipidemia medications, blood pres-
sure regulators, insulin, or glucose regulators were
also excluded (n = 429). The data for a total of 1423
participants without any missing variables were finally
included in the analysis.
Dependent variables and variables of interest
The dependent variables were the components of meta-
bolic syndrome. Waist circumference was measured at
the narrowest spot between the lowest rib and the high-
est lateral border of the right iliac crest. Systolic blood
pressure was measured after the participants relaxed for
5 min while sitting. Triplicate measurements of systolic
blood pressure were obtained. The mean of the second
and third measured value was used in the analysis. Tri-
glycerides, HDL cholesterol, and fasting glucose levels
were measured using the same Hitachi Automatic
Analyzer 7600–210 (Hitachi, Tokyo, Japan).
The variable of interest in this study was thyroid hor-
mone levels. Serum FT4, serum TSH, and TPOab levels
were measured using an electro-chemiluminescence
immunoassay (Cobas: Roche Diagnostics, Penzberg,
Germany). Samples were sent to the central certified la-
boratory and analyzed. The laboratory reference ranges
for FT4, TSH, and TPOab were 0.80–1.70 ng/dL, 0.50–5.0
uIU/mL, and < 34 IU/mL [14–16]. FT4 levels were divided
into five categories: (1) low; under normal (< 0.80 ng/dL);
(2) normal-low (< 1.17 ng/dL); (3) normal-middle (<
1.31 ng/dL); (4) normal-high (< 1.70 ng/dL); and (5) high;
upper normal (≥1.70 ng/dL). TSH levels were divided as
follows: low; under normal (< 0.50 uIU/mL); normal-low
(< 1.80 uIU/mL), normal-middle (< 2.87 uIU/mL),
normal-high (< 5.00 uIU/mL) and high; upper normal
(≥5.00 uIU/mL). TPOab levels were categorized as normal
(< 34 IU/mL), high with low FT4 (34 IU/mL ≤TPOab;
FT4 < 1.24 ng/dL), high with high FT4 (34 IU/mL ≤
TPOab; 1.24 ng/dL ≤ FT4). In addition, we categorized
TPOab levels into normal (< 34 IU/mL), high with low
Jang et al. BMC Endocrine Disorders  (2018) 18:29 Page 2 of 9
TSH (34 IU/mL ≤TPOab; TSH < 2.25 uIU/mL), high with
high TSH (34 IU/mL ≤TPOab; 2.25 uIU/mL ≤ FT4). Con-
sidering that the TPOab titer is related to both
hypothyroidism and hyperthyroidism, patients with high
levels were divided into two groups using two median
FT4 levels and two TSH levels.
Covariates
We adjusted for the covariates of sociodemographic fac-
tors, socioeconomic factors, health-behavior factors, and
health-condition factors. Sociodemographic factors in-
cluded age (19–44 years, 45–64 years, > 64 years) and
gender (male and female). Socioeconomic factors in-
cluded educational level (elementary school or less, mid-
dle school, high school, and college or over), marital
status (married and cohabit, married but no cohabit or
bereaved or divorced, and unmarried), household in-
come level (divided into quartiles), region (urban or
rural), and occupation (white collar, pink collar, blue col-
lar, and unemployed or else). Urban areas included capi-
tals and metropolitan cities and rural areas comprised
the remaining areas. Alcohol consumption (ever or
never), smoking (ever or never), and walking activity (ac-
tive or inactive) were the health-behavior factors.
Health-condition factors involved stress level (high, mid-
dle, low).
Statistical analysis
Statistical analysis was performed using the SAS soft-
ware, version 9.4 (SAS Institute, Cary, NC, USA). All
analysis incorporated weights. The mean values and
standard deviations of the components of metabolic syn-
drome were compared using the analysis of variance.
Multiple linear regression was performed to analyze the
relationship between thyroid hormone level and the
components of metabolic syndrome. Subgroup analysis
was performed according to age and gender. A p-value
< 0.05 was considered to indicate a statistically signifi-
cant result.
Results
Demographic characteristics
Table 1 presents the general characteristics of the study
populations. There were 683 males (48.0%) and 740 fe-
males (52.0%) included in this study. Of the 1423 partici-
pants, 870 (61.1%) were aged between 19 and 44 years,
471 participants (33.1%) were aged between 45 and
64 years, and 82 participants (5.8%) were aged over
64 years. The mean waist circumference was 31.9 ±
4.0 in. and the mean triglycerides level was 133.0 ±
120.5 mg/dL. The mean HDL cholesterol level was 52.0
± 12.8 mg/dL, mean blood pressure 114.2 ± 15.1 mmHg,
and the mean fasting glucose level 95.0 ± 16.6 mg/dL.
When analyzed according to FT4 levels, waist
circumference, triglycerides, and fasting glucose results
were statistically significantly different (p < 0.05). Pa-
tients with high FT4 levels demonstrated considerably
higher fasting glucose levels (High: 109.4 ± 45.2 mg/dL;
Normal-middle: 93.8 ± 12.2 mg/dL).
Multiple analysis
Table 2 shows the estimates for the components of
metabolic syndrome. “β” presents standardized regres-
sion coefficient and “S.E” presents standardized error of
a correlation coefficient. After controlling for covariates,
the results showed a positive association between FT4
and fasting glucose level in patients with high FT4 levels
when compared to those with normal-middle FT4 levels
(β = 15.992; p = < 0.0001). We also identified a significant
negative association between FT4 levels and triglycerides
in patients with normal-high (β = − 21.145, p = 0.0054)
and those with high FT4 levels (β = − 49.713, p = 0.0404).
In addition, a positive association was observed between
TPOab and triglycerides levels in patients with high
TPOab levels in the presence of low median FT4 levels
(β = 36.075, p = 0.0247). Also, positive association was
identified between TPOab and triglycerides levels in pa-
tients with high TPOab levels in the presence of high
median TSH levels (β = 32.181, p = 0.0368).
Sensitivity analysis
Table 3 shows the subgroup analysis of the association
between the components of metabolic syndrome and
FT4 hormone levels according to age and gender. When
stratified by age, a significant negative association be-
tween FT4 and triglycerides was observed among pa-
tients aged 19–44 years (low: β = 124.396, p = 0.0165;
normal-high: β = − 25.519, p = 0.0050). This association
was stronger in the 19–44-year-old age group than in
the other older age groups.
Additional file 1: Table S1 presents the subgroup ana-
lysis of the association between the components of
metabolic syndrome and TSH levels stratified by age
and gender. Additional file 1: Table S2 shows the sub-
group analysis of the association between the compo-
nents of metabolic syndrome and TPOab levels with
categorizing FT4 levels stratified by age and gender. In
addition, Additional file 1: Table S3 shows the subgroup
analysis of the association between the components of
metabolic syndrome and TPOab levels with categorizing
TSH levels stratified by age and gender. TSH was not
significantly associated with other components of meta-
bolic syndrome, except HDL cholesterol. Additional
file 1: Table S2 shows that a positive association between
TPOab and triglycerides levels is more frequently ob-
served in male with high TPOab titers but with low FT4
levels (β = 136.104, p = 0.0062).
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Table 3 Subgroup analysis of components of metabolic syndromes with free thyroxine hormone levels stratified by age and gender
Variables Free thyroxine hormone levels
Low Normal (low tertile) Normal
(mid tertile)
Normal (high tertile) High
βa S.E p-value βa S.E p-value βa βa S.E p-value βa S.E p-value
Waist circumference
Age
19~ 44 3.248 1.715 0.0586 0.400 0.345 0.2471 Ref. −0.537 0.300 0.0738 −1.062 0.892 0.2343
45~ 64 0.745 1.113 0.5037 0.470 0.352 0.1818 Ref. 0.078 0.410 0.8495 0.394 1.668 0.8134
64< −1.085 3.667 0.7684 −0.026 0.927 0.9777 Ref. −1.638 1.226 0.1868 −3.990 3.705 0.2859
Gender
Male 1.998 2.172 0.3580 0.804 0.405 0.0477 Ref. −0.270 0.336 0.4206 −0.684 0.957 0.4749
Female 1.481 0.982 0.1322 0.070 0.284 0.8061 Ref. −0.556 0.328 0.0909 −2.002 1.277 0.1173
Triglycerides
Age
19~ 44 124.396 51.798 0.0165 10.341 10.430 0.3217 Ref. −25.519 9.066 0.0050 −49.843 26.938 0.0646
45~ 64 22.880 41.955 0.5858 14.699 13.253 0.2680 Ref. −11.085 15.441 0.4732 −78.026 62.873 0.2153
64< −29.035 77.925 0.7108 −6.737 19.693 0.7335 Ref. 20.424 26.056 0.4363 −21.240 78.744 0.7883
Gender
Male −8.759 88.150 0.9209 19.926 16.443 0.2260 Ref. −29.603 13.619 0.0301 −56.536 38.816 0.1457
Female 59.246 19.538 0.0025 6.175 5.645 0.2744 Ref. −8.730 6.527 0.1815 −39.210 25.395 0.1230
HDL cholesterol
Age
19~ 44 −3.987 5.399 0.4605 0.135 1.096 0.9021 Ref. 2.554 0.952 0.0075 −0.867 2.954 0.7692
45~ 64 0.799 4.276 0.8518 −1.313 1.360 0.3348 Ref. −1.687 1.581 0.2868 −5.880 6.408 0.3594
64< 6.579 10.435 0.5309 −1.360 2.688 0.6149 Ref. 3.663 3.507 0.3007 10.076 10.581 0.3450
Gender
Male −4.968 6.373 0.4360 −0.661 1.201 0.5824 Ref. 1.028 0.994 0.3017 0.343 2.981 0.9085
Female 1.003 3.743 0.7888 0.050 1.089 0.9634 Ref. 1.908 1.256 0.1292 −3.308 4.865 0.4968
Blood pressure
Age
19~ 44 9.081 5.089 0.0747 −0.032 1.029 0.9751 Ref. 0.639 0.893 0.4741 1.560 2.646 0.5556
45~ 64 −4.007 5.626 0.4767 −2.552 1.779 0.1522 Ref. −3.081 2.075 0.1382 −1.728 8.439 0.8378
64< −12.387 20.182 0.5417 5.314 5.101 0.3017 Ref. −2.610 6.749 0.7003 22.083 20.395 0.2833
Gender
Male −12.655 7.995 0.1139 2.073 1.497 0.1666 Ref. −0.438 1.239 0.7239 2.575 3.522 0.4649
Female 4.899 3.870 0.2060 −2.082 1.122 0.0638 Ref. − 0.001 1.294 0.9996 3.303 5.030 0.5116
Fasting glucose
Age
19~ 44 −3.880 7.421 0.6012 1.190 1.494 0.4261 Ref. 1.333 1.299 0.3050 17.139 3.859 <.0001
45~ 64 5.895 5.216 0.2591 1.833 1.648 0.2665 Ref. −2.049 1.920 0.2865 14.249 7.817 0.0690
64< 13.834 18.440 0.4561 −0.592 4.660 0.8994 Ref. 1.248 6.166 0.8403 3.026 18.633 0.8715
Gender
Male 0.545 11.505 0.9623 3.968 2.146 0.0649 Ref. −0.335 1.778 0.8506 21.236 5.066 <.0001
Female 3.278 3.480 0.3466 0.346 1.006 0.7307 Ref. 1.431 1.163 0.2187 5.173 4.524 0.2532
aModel is adjusted by age, gender, education level, marital status, household income level, region, occupation, alcohol consumption, smoking, walking activity
and stress level
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Discussion
The purpose of this study was to identify whether any
associations exist between thyroid hormone levels and
metabolic syndrome components. Thyroid dysfunction
is well known to affect glucose and lipid metabolism; ab-
normal glucose level and abnormal lipid profile are im-
portant factors of metabolic syndrome [17]. In our
study, we found that glucose and lipid metabolism were
associated with thyroid dysfunction. A significant posi-
tive association was observed between fasting glucose
and FT4 in patients with high FT4 levels. In terms of
lipid metabolism, a negative association between triglyc-
erides and FT4 was observed among people with
normal-high or high FT4 levels. In addition, there was a
significant positive association between TPOab and tri-
glycerides levels in patients with high thyroid peroxidase
levels and with low median FT4 levels.
Thyroid hormones regulate carbohydrate metabolism
[18]. They influence the mRNA and protein expression of
the glucose transporter 4, AMP-activated protein kinase,
and acetyl CoA carboxylase in skeletal muscle [19]. Hyper-
thyroidism usually occurs when high FT4 levels leads to
its increased production and absorption from glycogen,
lactic acid, glycerol, and amino acids [20]. Hyperthyroid-
ism can also increase insulin degradation. Which deterio-
rates blood glucose control [19, 20]. Based on these
mechanisms, other studies also showed that glucose levels
are high in patients with hyperthyroidism [21]. Foss et al.
demonstrated that patients with hyperthyroidism had
higher blood glucose levels than the euthyroid partici-
pants, indicating increased endogenous glucose produc-
tion [22]. Moreover, Roubsanthisuk et al. reported that the
higher glucose intolerance showed common in hyperthy-
roidism compare to the normal participants [23]. This
could be a major cause of the increased risk for diabetes
[23]. Health professionals should conduct follow-up tests
of the glucose level of patients with high thyroid hormone
levels. Additionally, thyroid hormone levels should be
checked regularly in patients with high glucose levels.
A significant negative association between FT4 levels and
triglycerides was observed in patients with high-normal or
high FT4 levels. To explain this, we presumed that thyroid
hormones play a key role in the regulation of enzyme activity
during lipoprotein transport [12]. The influence of thyroid
function on lipid metabolism involves a pathophysiological
process [24]. The negative association observed between tri-
glycerides and thyroid hormones can be explained by the in-
creased removal rate of triglycerides from plasma due to an
increase in the activity of hepatic triglyceride lipase [25, 26].
The effects of thyroid hormone on lipid metabolism are well
known [26]. Because the lipid profile tends to normalize im-
properly under high thyroid hormone levels, the lipid profile
needs to be followed up after adjusting for thyroid hormone
levels [25].
There was a significant positive association between
TPOab and triglycerides levels in patients with high thy-
roid peroxidase levels but with low median FT4 levels.
In addition, a positive association was identified between
TPOab and triglycerides levels in patients with high thy-
roid peroxidase levels in the presence of high median
TSH levels. The presence of TPOab in the blood indi-
cates a high risk for thyroid disease due to autoimmune
disorders [27, 28]. In fact, abnormal TPOab levels were
observed in 90% of patients with hypothyroidism and
Graves’ disease [27, 28]. Therefore, the positive associ-
ation between TPOab and triglycerides levels in patients
with high thyroid peroxidase levels but low median FT4
levels may be related to hypothyroidism.
Based on the results of the subgroup analysis, a signifi-
cant negative association was observed between FT4 and
triglyceride levels in patients aged 19–44 years; this asso-
ciation was stronger in the 19–44-year-old age group
than in the other older age groups. This finding empha-
sizes the possibility of accumulation of risk through
one’s life course. Accumulation of various risks increases
owing to illness, health-damaging behaviors, and adverse
environmental conditions [29]. Older people may have
more risk factors owing to their risk accumulation, and
are more likely to have unmeasured risk factors that we
could not adjust for [30]. To address this issue, future
studies developed to understand the association between
thyroid hormones and metabolic syndrome should in-
corporate a panel design.
This study had some limitations. First, the study was
based on a cross-sectional survey. Causality could not be
confirmed clearly and only the association could be con-
firmed. Second, one of the major thyroid hormones, tri-
iodothyronine, was not used in the thyroid function tests.
Despite the above limitations, this study also has a few
strengths. First, consistent blood tests showed accurate
blood TSH levels. Second, most of the previous studies
were conducted in Caucasians; therefore, this issue is
worth pursuing among Koreans. Finally, this study used
the most recent (KNHANES 2013–2015) nationally,
multistage, stratified collected data and could therefore be
considered to be representative of the Korean population.
Conclusion
FT4 showed a partially positive association with fasting glu-
cose, and a partially negative association with triglycerides
in the general Korean population. Glucose level and lipid
profile are metabolic syndrome components; metabolic syn-
drome is strongly correlated with diseases such as diabetes
and cardiovascular disease that are associated with high
mortality and morbidity rates. In patients with abnormal
thyroid function, follow up tests for metabolic syndrome
components during thyroid dysfunction could prevent over-
looking metabolic syndrome and prevent related diseases.
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